Post-menopausal bleeding causes
Endometrial Hyperplasia (Including EIN) After Menopause
Endometrial hyperplasia means thickening of the uterine lining. Hyperplasia with atypia (also called EIN) is clinically important because it can coexist with, or progress to, endometrial cancer.
Quick definition
Hyperplasia is overgrowth of endometrial tissue. EIN/atypia is the higher-risk form.
Risk factors often overlap with endometrial cancer risk and include prolonged unopposed estrogen exposure.
When to seek urgent care
- Heavy bleeding with dizziness, weakness, or fainting.
- Persistent bleeding despite initial treatment.
- Bleeding with severe pain, fever, or feeling very unwell.
If you are unsure, contact reception or your nearest emergency centre.
What this usually means
- Hyperplasia without atypia usually has lower progression risk than EIN/atypical hyperplasia.
- EIN/atypia needs prompt specialist management because concurrent cancer can be present.
- Management decisions depend on pathology subtype, symptoms, and overall risk profile.
How this is assessed
Diagnosis is made with endometrial tissue sampling. Imaging may support evaluation, but histology drives management.
Step 1
Confirm tissue diagnosis
Endometrial sampling defines whether hyperplasia is without atypia or EIN/atypia.
Step 2
Risk stratification
We review risk factors, menopausal status, and whether concurrent cancer is likely.
Step 3
Choose treatment pathway
Pathology and patient factors determine medical versus surgical management.
Step 4
Planned surveillance
Repeat sampling/follow-up ensures treatment response and early detection of progression.
Treatment options by situation
Treatment depends on subtype. EIN/atypia generally needs more definitive management than non-atypical hyperplasia.
Progestin-based treatment
Used in selected pathways, often with repeat sampling to document response.
Definitive surgical pathway
Hysterectomy is often recommended for EIN/atypia in post-menopausal patients.
What happens next
Your pathology result is the key driver of next steps and follow-up intensity.
- Agree on medical versus surgical pathway based on subtype and risk.
- Use scheduled repeat sampling when conservative treatment is chosen.
- Escalate promptly if bleeding persists or pathology progresses.
With EIN/atypia, treatment is generally more urgent and definitive because of progression and coexistence risk.
Next step: assessment helps us confirm diagnosis early and choose the right treatment pathway safely.
Common questions
Frequently asked questions
Is hyperplasia the same as cancer?
No. But EIN/atypia is higher risk and can coexist with cancer, so management is proactive.
Can hyperplasia be treated without surgery?
Some forms can be managed medically with close surveillance, depending on subtype and overall risk.
Why do I need repeat biopsies?
They show whether treatment is working and whether risk is decreasing or increasing.
Need a plan today? We can assess urgency, explain findings clearly, and map your next steps.
Still unsure? We can map your symptoms to the right pathway and agree on practical next steps.